Neuroone Medical Technologies is trading 6.5% up at $1.80 following strong follow-through from physician-reported outcomes in a Mayo Clinic study of its brain ablation device for epilepsy.
- The clinical data, which previously lifted shares in after-hours trading, continues to drive significant momentum for the company.
- While broader U.S. markets are also trending higher, today's strength appears primarily tied to this company-specific clinical news rather than macro factors.